1 Vote
1 Contributor
1425 Views 
0 SavedYou might also be interested in
Dear All, There are various types of cancer. Kindly talk to our medical expert on 8010994994 for better assessment and advice.
According to many studies, breast cancer is more common in women whose family members or blood relatives have also had breast cancer. This means that it is mostly genetic. Other factors like Radiation exposure, obesity, alcohol consumption, not having children, can all participate as risk factors fo....
treatment for tumor in the liver depends on the kind of tumor and its extent. please share your reports for a better advice.
Receive guidance from the first consultation through the entire hospitalization process.
Medical experts assist the patients to find the right doctor and book appointments.
Consult with 5000+ doctors online and get all your health queries answered.
Mahima Chaudhary
Receptors are proteins in or on cells that can attach to certain substances in the blood. Normal breast cells and some breast cancer cells have receptors that attach to the hormones estrogen and progesterone, and depend on these hormones to grow.
The breast tissue estrogen receptor is both genetic and variable in the presence of chemotherapy and other medications.
Breast cancer cells may have one, both, or none of these receptors.
ER-positive: Breast cancers that have estrogen receptors are called ER-positive (or ER+) cancers.
PR-positive: Breast cancers with progesterone receptors are called PR-positive (or PR+) cancers.
Keeping these receptors from attaching to the hormones can help keep the cancer from growing and spreading. There are drugs that can be used to do this.
Knowing the hormone receptor status of your cancer helps doctors decide how to treat it. If your cancer has one or both of these hormone receptors, hormone therapy drugs can be used to either lower estrogen levels or stop estrogen from acting on breast cancer cells. This kind of treatment is helpful for hormone receptor-positive breast cancers, but it doesn’t work on tumors that are hormone receptor-negative (both ER- and PR-negative).